• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Impel NeuroPharma Inc.

    5/7/21 4:30:17 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMPL alert in real time by email
    SC 13D 1 brhc10024205_sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No.   )*

    Impel NeuroPharma, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    45258K109
    (CUSIP Number)

    David J. Sorkin, Esq.
    Kohlberg Kravis Roberts & Co. L.P.
    30 Hudson Yards
    New York, New York 10001
    Telephone: (212) 750-8300
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    April 27, 2021
    (Date of Event Which Requires Filing of This Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [  ]

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.


    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 45258K109
    13D
    Page 1 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Iris Investors LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 2 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Health Care Strategic Growth Fund L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 3 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Associates HCSG L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 4 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR HCSG GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 5 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Group Partnership L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 6 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Group Holdings Corp.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 7 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR & Co. Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 8 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Management LLP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,802,638
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 9 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Henry R. Kravis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    3,802,638
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 10 of 18 pages

    1
    NAMES OF REPORTING PERSONS
     
     
    George R. Roberts
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    3,802,638
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    3,802,638
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,802,638
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 45258K109
    13D
    Page 11 of 18 pages

    Item 1.
    Security and Issuer.

    This Statement on Schedule 13D (this “Schedule 13D”) relates to common stock, par value $0.001 per share (the “Common Stock”), of Impel NeuroPharma, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 201 Elliott Avenue West, Suite 260, Seattle, WA 98119.
     
    Item 2.
    Identity and Background.
     
    (a), (f) This Schedule 13D is being filed pursuant to Rule 13d-1(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by:
     

    (i)
    KKR Iris Investors LLC, a Delaware limited liability company;
     

    (ii)
    KKR Health Care Strategic Growth Fund L.P., a Delaware limited liability partnership;
     

    (iii)
    KKR Associates HCSG L.P., a Delaware limited partnership;
     

    (iv)
    KKR HCSG GP LLC, a Delaware limited liability company;
     

    (v)
    KKR Group Partnership L.P., a Cayman Islands exempted limited partnership;
     

    (vi)
    KKR Group Holdings Corp., a Delaware corporation;
     

    (vii)
    KKR & Co. Inc., a Delaware corporation;
     

    (viii)
    KKR Management LLP, a Delaware limited liability partnership;
     

    (ix)
    Henry R. Kravis, a United States citizen; and
     

    (x)
    George R. Roberts, a United States citizen (the persons and entities listed in items (i) through (x) are collectively referred to herein as the “Reporting Persons”).
     
    KKR Health Care Strategic Growth Fund L.P. is the managing member of KKR Iris Investors LLC. KKR Associates HCSG L.P. is the general partner of KKR Health Care Strategic Growth Fund L.P. KKR HCSG GP LLC is the general partner of KKR Associates HCSG L.P. KKR Group Partnership L.P. is the sole member of KKR HCSG GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR & Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP.
     
    Each of Messrs. Joseph Bae, Scott Nuttall, Robert Lewin and David Sorkin is a director of KKR Group Holdings Corp. The executive officers of KKR Group Holdings Corp. and KKR & Co. Inc. are Messrs. Kravis, Roberts, Bae, Nuttall, Lewin and Sorkin. The directors of KKR & Co. Inc. are listed on Annex A attached hereto, which is incorporated herein by reference.


    CUSIP No. 45258K109
    13D
    Page 12 of 18 pages

    Each of Messrs. Bae, Nuttall and Sorkin is a United States citizen. Mr. Lewin is a Canadian citizen.
     
    The Reporting Persons have entered into a joint filing agreement, a copy of which is attached hereto as Exhibit A.
     
    (b)     The address of the business office of each of the Reporting Persons, except for Mr. Roberts, and Messrs. Bae, Nuttall, Lewin and Sorkin and the other individuals named in this Item 2 is:
     
    c/o Kohlberg Kravis Roberts & Co. L.P.
    30 Hudson Yards
    New York, New York 10001

    The address of the principal business office of Mr. Roberts is:

    c/o Kohlberg Kravis Roberts & Co. L.P.
    2800 Sand Hill Road, Suite 200
    Menlo Park, CA 94025
     
    (c)          Each of KKR Group Partnership L.P., KKR Group Holdings Corp., KKR & Co. Inc. and KKR Management LLP is principally engaged as a holding company. KKR Iris Investors LLC is engaged in the business of investing in securities and KKR Health Care Strategic Growth Fund L.P., KKR Associates HCSG L.P., and KKR HCSG GP LLC are each principally engaged in the business of being a general partner or sole or managing member, as described above, and managing investments through other partnerships and limited liability companies.
     
    The present principal occupation or employment of each of Messrs. Kravis, Roberts, Bae, Nuttall, Lewin and Sorkin is as an executive of Kohlberg Kravis Roberts & Co. L.P. (“KKR”) and/or one or more of its affiliates. The present principal occupation of each of the other individuals named in Item 2 is listed on Annex A.
     
    (d)          During the last five years, none of the Reporting Persons or, to the best knowledge of the Reporting Persons, any of the other individuals named in this Item 2, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     
    (e)          During the last five years, none of the Reporting Persons or, to the best knowledge of the Reporting Persons, any of the other individuals named in this Item 2, has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


    CUSIP No. 45258K109
    13D
    Page 13 of 18 pages

    Item 3.
    Source and Amount of Funds or Other Consideration.

    In December 2018, KKR Iris Investors LLC purchased 42,307,448 shares of Series D redeemable convertible preferred stock (“Series D Preferred Stock”) from the Issuer at a purchase price of $0.7091 per share for an aggregate purchase price of $30,000,000. Each 16.37332 shares of Series D Preferred Stock automatically converted into one share of Common Stock upon the completion of the Issuer’s initial public offering.

    In March 2021, the Issuer issued a convertible promissory note (the “Note”) to KKR Iris Investors LLC for an aggregate amount of $1,591,072. The Note automatically converted into shares of Common Stock on April 27, 2021 upon the closing of the Issuer’s initial public offering at 90% of the $15.00 initial public offering price, which resulted in an acquisition of 118,712 shares of Common Stock.

    On April 27, 2021, in connection with the closing of the Issuer’s initial public offering, KKR Iris Investors LLC purchased an additional 1,100,000 shares of Common Stock from the Issuer in a private placement for a price of $15.00 per share, which was the public offering price per share of Common Stock in the initial public offering.

    The source of funds required for the purchases are from capital contributions from investors in KKR Iris Investors LLC.

    Item 4.
    Purpose of Transaction.
     
    The information set forth in Items 3 and 6 of this Schedule 13D is hereby incorporated by reference into this Item 4.
     
    The Reporting Persons acquired the securities reported herein for investment purposes and intend to review their investments in the Issuer on a continuing basis. Subject to the terms of the Investors’ Rights Agreement and Lock-Up Agreement (each defined in Item 6 below) and various factors, including but not limited to the Issuer’s financial position and strategic direction, price levels of the Common Stock, conditions in the securities markets, various laws and regulations applicable to the Issuer and companies in its industry and the Reporting Persons’ ownership in the Issuer, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including changing their current intentions, with respect to any or all matters required to be disclosed in this Schedule 13D. Without limiting the foregoing, the Reporting Persons may, from time to time, acquire or cause affiliates to acquire additional shares of Common Stock or other securities of the Issuer (including any combination or derivative thereof). Subject to the limitations set forth in the Lock-Up Agreement, the Reporting Persons intend to dispose, or cause affiliates to dispose, of shares of Common Stock or other securities of the Issuer from time to time, and may continue to hold, or cause affiliates to hold, shares of Common Stock or other securities of the Issuer.
     
    The Reporting Persons intend to engage in discussions with management or the board of directors of the Issuer about its business, operations, strategy, plans and prospects, from time to time. In addition, the Reporting Persons may engage in discussions with management or the
     

    CUSIP No. 45258K109
    13D
    Page 14 of 18 pages

    board of directors of the Issuer, stockholders or other securityholders of the Issuer and other relevant parties or take other actions concerning any extraordinary corporate transaction (including, but not limited to, a merger, reorganization or liquidation), a sale or transfer of a material amount of assets, a change in the board of directors or management, a material change in the capitalization or dividend policies, other material changes in the Issuer’s business or corporate structure, changes in the Issuer’s charter, bylaws or other actions that may impede the acquisition of control, de-listing or de-registration of the Issuer, or similar actions.
     
    Mr. Ali Satvat, an executive of KKR, is currently a member of the board of directors of the Issuer.
     
    Except as set forth above, or as would occur upon completion of any of the matters discussed herein, the Reporting Persons and, to the best knowledge of the Reporting Persons, each of the other individuals named in Item 2 above, have no present plans, proposals or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Although the foregoing reflects activities presently contemplated by the Reporting Persons and each other individuals named in Item 2 with respect to the Issuer, the foregoing is subject to change at any time.
     
    Item 5.
    Interest in Securities of the Issuer.
     
    The information set forth in Annex A of this Schedule 13D and the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5.
     
    (a) and (b).          The Reporting Persons may be deemed to beneficially own an aggregate of 3,802,638 shares of Common Stock, which represents, in the aggregate, approximately 19.6% of the outstanding shares of Common Stock.
     
    The percentage of beneficial ownership in this Schedule 13D is based on 19,414,834 shares of Common Stock outstanding as of April 27, 2021, after giving effect to the consummation of the Issuer’s initial public offering and the related transactions, as set forth in the Issuer’s prospectus dated April 22, 2021, filed with the Securities and Exchange Commission on April 23, 2021.
     
    Each of KKR Health Care Strategic Growth Fund L.P. (as the managing member of KKR Iris Investors LLC); KKR Associates HCSG L.P. (as the general partner of KKR Health Care Strategic Growth Fund L.P.); KKR HCSG GP LLC (as the general partner of KKR Associates HCSG L.P.); KKR Group Partnership L.P. (as the sole member of KKR HCSG GP LLC); KKR Group Holdings Corp. (as the general partner of KKR Group Partnership L.P.); KKR & Co. Inc. (as the sole shareholder of KKR Group Holdings Corp.); KKR Management LLP (as the Series I preferred stockholder of KKR & Co. Inc.); and Messrs. Kravis and Roberts (as the founding partners of KKR Management LLP) may be deemed to be the beneficial owner of the shares held by KKR Iris Investors LLC.
     
    The filing of this Schedule 13D shall not be construed as an admission that any of the above-listed entities or individuals is the beneficial owner of any securities covered by this Schedule 13D.
     

    CUSIP No. 45258K109
    13D
    Page 15 of 18 pages

    To the best knowledge of the Reporting Persons, none of the individuals named in Item 2 beneficially owns any shares of Common Stock except as described herein.
     
    (c)          Except as otherwise described in Item 3 of this Schedule 13D, none of the Reporting Persons, or, to the best knowledge of the Reporting Persons, any other individual named in Item 2, has engaged in any transaction in any shares of Common Stock during the past 60 days.
     
    (d)          To the best knowledge of the Reporting Persons, no one other than the Reporting Persons, or the partners, members, affiliates or shareholders of the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of the Issuer reported as beneficially owned by the Reporting Persons herein.
     
    (e)          Not applicable.
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
     
    The information set forth in Items 3, 4 and 5 hereof is hereby incorporated by reference into this Item 6.
     
    Investors’ Rights Agreement
     
    On December 4, 2018, the Issuer entered into an amended and restated investors’ rights agreement (the “Investors’ Rights Agreement”) with certain holders of the Issuer’s redeemable convertible preferred stock, including KKR Iris Investors LLC. Pursuant to the Investors’ Rights Agreement, the Issuer agreed to register an aggregate of 12,605,800 shares of Common Stock, including the 2,583,926 shares of Common Stock acquired by KKR Iris Investors LLC upon conversion of the Series D Preferred Stock. KKR Iris Investors LLC and the other parties to the Investors’ Rights Agreement also have piggyback registration rights. The registration rights set forth in the Investor’s Rights Agreement are subject to certain limitations, conditions and other terms.
     
    The registration rights terminate five years following the completion of the Issuer’s initial public offering or, with respect to any particular stockholder, at the time that stockholder can sell all of its shares during any 90-day period pursuant to Rule 144 of the Securities Act.
     
    Lock-Up Agreement
     
    In connection with the Issuer’s initial public offering, KKR Iris Investors LLC entered into a lock-up agreement (the “Lock-Up Agreement”) with Cowen and Company, LLC and Guggenheim Securities, LLC, whereby KKR Iris Investors LLC agreed, subject to certain exceptions, not to dispose of or hedge any shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock for a period of 180 days from April 22, 2021, except with the prior written consent of Cowen and Company, LLC and Guggenheim Securities, LLC.


    CUSIP No. 45258K109
    13D
    Page 16 of 18 pages

    The foregoing descriptions of the Investors’ Rights Agreement and the Lock-Up Agreement do not purport to be complete and are qualified in their entirety by reference to such documents, copies of which are filed as Exhibits to this Schedule 13D and are incorporated herein by reference.
     
     Item 7.
    Materials to be Filed as Exhibits
     
    Exhibit Number
     
    Description
    Exhibit A
     
    Joint Filing Agreement by and among the Reporting Persons
    Exhibit B
     
    Powers of Attorney
    Exhibit C
     
    Investors’ Rights Agreement (incorporated herein by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1, filed on April 2, 2021)
    Exhibit D
     
    Lock-Up Agreement


    CUSIP No. 45258K109
    13D
    Page 17 of 18 pages

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:          May 7, 2021

     
    KKR IRIS INVESTORS LLC
     
    By:
    Health Care Strategic Growth Fund L.P., its managing member
     
    By:
    KKR Associates HCSG L.P., its general partner
     
    By:
    KKR HCSG GP LLC, its general partner
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Director

     
    HEALTH CARE STRATEGIC GROWTH FUND L.P.
     
    By:KKR Associates HCSG L.P., its general partner
     
    By:KKR HCSG GP LLC, its general partner
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Director
         
     
    KKR ASSOCIATES HCSG L.P.
     
    By:KKR HCSG GP LLC, its general partner
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Director
         
     
    KKR HCSG GP LLC
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Director


    CUSIP No. 45258K109
    13D
    Page 18 of 18 pages

     
    KKR GROUP PARTNERSHIP L.P.
     
    By: KKR Group Holdings Corp. its general partner
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Chief Financial Officer
         
     
    KKR GROUP HOLDINGS CORP.
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Chief Financial Officer
         
     
    KKR & CO. INC.
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Chief Financial Officer
         
     
    KKR MANAGEMENT LLP
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact for
       
    Robert H. Lewin, Chief Financial Officer
         
     
    HENRY R. KRAVIS
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact
         
     
    GEORGE R. ROBERTS
         
     
    By:
    /s/ Terence P. Gallagher
     
    Name:
    Terence P. Gallagher
     
    Title:
    Attorney-in-fact


    Annex A

    Directors of KKR & Co. Inc.

    The following sets forth the name and principal occupation of each of the directors of KKR & Co. Inc. Each of such persons is a citizen of the United States other than Xavier Niel, who is a citizen of France, and Arturo Gutiérrez, who is a citizen of Mexico.

    Name
     
    Principal Occupation
    Henry R. Kravis
     
    Co-Chief Executive Officer, Co-Chairman of KKR & Co. Inc.
    George R. Roberts
     
    Co-Chief Executive Officer, Co-Chairman of KKR & Co. Inc.
    Joseph Y. Bae
     
    Co-President, Co-Chief Operating Officer of KKR & Co. Inc.
    Scott C. Nuttall
     
    Co-President, Co-Chief Operating Officer of KKR & Co. Inc.
    Mary N. Dillon
     
    Chief Executive Officer of Ulta Beauty, Inc.
    Joseph A. Grundfest
     
    William A. Franke Professor of Law and Business of Stanford Law School
    Arturo Gutiérrez
     
    Chief Executive Officer of Arca Continental, S.A.B. de C.V.
    John B. Hess
     
    Chief Executive Officer of Hess Corporation
    Dane Holmes
     
    Chief Executive Officer and Co-Founder of Eskalera Inc.
    Xavier Niel
     
    Founder, Deputy Chairman of the Board and Chief Strategy Officer of Iliad SA
    Patricia F. Russo
     
    Retired, Former Chief Executive Officer of Alcatel-Lucent
    Thomas M. Schoewe
     
    Retired, Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.
    Robert W. Scully
     
    Retired, Former Member, Office of the Chairman of Morgan Stanley
     


    Get the next $IMPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMPL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

      Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

      12/19/23 11:10:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

      SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support

      10/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

      SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

      5/10/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

      SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

      4/12/23 4:01:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Financials

    Live finance-specific insights

    See more
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

      SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan

      5/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i

      3/24/23 8:17:18 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen initiated coverage on Impel NeuroPharma with a new price target

      Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

      5/18/21 7:57:51 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Impel NeuroPharma with a new price target

      Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Impel NeuroPharma with a new price target

      Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      12/4/23 5:12:05 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      11/15/23 4:06:46 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      10/6/23 5:10:06 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Impel Pharmaceuticals Inc.

      EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/16/24 12:15:09 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:21:28 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:19:30 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/13/21 2:21:35 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/7/21 1:04:43 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Smith Brandon D

      3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/26/23 4:32:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vivo Capital Viii, Llc sold $74,131 worth of shares (575,000 units at $0.13) (SEC Form 4)

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/19/23 6:00:01 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brookfield Corp /On/

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/4/23 9:00:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care